IN8bio, Inc. $INAB Shares Sold by AIGH Capital Management LLC

AIGH Capital Management LLC lowered its position in IN8bio, Inc. (NASDAQ:INAB) by 89.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 149,895 shares of the company’s stock after selling 1,300,105 shares during the quarter. AIGH Capital Management LLC owned 4.95% of IN8bio worth $313,000 as of its most recent filing with the Securities and Exchange Commission.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of IN8bio in a report on Wednesday, October 8th. Zacks Research upgraded IN8bio from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 14th. Mizuho set a $4.00 target price on IN8bio in a report on Monday, October 13th. Finally, Wall Street Zen upgraded IN8bio from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $92.00.

IN8bio Trading Down 1.9%

Shares of INAB opened at $2.07 on Monday. The stock’s 50-day moving average is $2.19 and its two-hundred day moving average is $3.02. The stock has a market cap of $9.40 million, a PE ratio of -0.23 and a beta of 0.03. IN8bio, Inc. has a 12 month low of $1.91 and a 12 month high of $16.70. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.03 and a quick ratio of 7.03.

IN8bio (NASDAQ:INAB) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($1.24) EPS for the quarter, topping analysts’ consensus estimates of ($1.50) by $0.26. Equities analysts forecast that IN8bio, Inc. will post -0.56 earnings per share for the current fiscal year.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.